Top 3 formulary access takeaways for pharma
Three items you need to know from "Formulary Fireworks"
The drugmaker said it has been forced to provide higher rebates to PBMs and insurers for certain drugs.
Pharma and biotech can bolster their value through the analytics efforts of their health economics and outcomes teams.
The idea is that each gets some of what it needs. Payers gain some control over cost, and pharma may get to stay on formulary.